Pulse Biosciences, Inc. PLSE Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

EyePoint, Inc. EYPT

$297K+119%

TRV

Trevi Therapeutics, Inc.TRVI

$0—

Rumble, Inc.RUM

$29.43M+32,132%

MBX Biosciences, Inc.MBX

$378K—

NovaGold ResourcesNG

$0-100%

Essential Properties Realty TrustEPRT

$152K-35.6%

Other financials

Income statement

See full

Revenue$401.0K—

Gross profit$31.0K—

Operating income-$19.2M-6.1%

Net income-$18.6M-10.6%

EPS (diluted)-$0.49-2.1%

Balance sheet

See full

Cash & equivalents$68.3M-42.7%

Total debt$7.2M-16.6%

Total equity$66.3M-44.0%

Total assets$81.6M-38.8%

Cash flow

See full

Operating cash flow-$14.6M-7.9%

CapEx$33.0K-26.7%

Free cash flow-$14.6M-7.8%

Valuation

See full

Market cap$1.77B+38.4%

Profitability

See full

Gross margin-4,067.5%—

Operating margin-10,392.1%—

Net margin-9,929%—

FCF margin-7,390%—

Returns & leverage

See full

Return on equity-80.7%+3.1pp

Debt / equity0.1×0.0×

Current ratio7.3×-8.3×

Where this comes from

Reported directly by Pulse Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulse Biosciences, Inc.'s payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pulse Biosciences, Inc.'s payments of stock issuance costs?: Pulse Biosciences, Inc. (PLSE) reported payments of stock issuance costs of $57K in Q1 2026.